Acasti Pharma Inc. (ACST) Jun 2024 Earnings Report
Acasti Pharma, Inc.: Investment Report
Overview
Acasti Pharma, Inc. is a biotechnology company focused on developing and commercializing pharmaceutical products for rare and orphan diseases. With a market capitalization of $31.02 million, Acasti Pharma presents an attractive opportunity for investors seeking exposure to the growing orphan disease market. This report provides an in-depth analysis of Acasti Pharma's financial performance, growth prospects, and recent news, making it a must-read for investors considering a position in ACST.
Core Metrics
- Current price: $3.30
- 52-week high: $3.84
- 52-week low: $1.72
- Market Cap: $31.02 million
- P/E Ratio: N/A
- Earnings per Share: -$5.68
- 50-day average: $2.95
- 200-day average: $2.71
- Analyst Recommendations: Buy (1 analyst)
Financial Performance
Acasti Pharma's financial performance has been marked by significant losses, with an EBITDA of -$11.36 million and operating cash flow of -$12.33 million. However, the company's cash position remains strong, with $23.01 million in total cash. The recent private placement equity financing of $7.5 million provides additional liquidity to support the company's operations.
Growth Prospects
Acasti Pharma's lead product candidate, GTX-104, is an intravenous infusion to treat subarachnoid hemorrhage, a rare and life-threatening condition. The company's patient enrollment in the pivotal STRIVE-ON Phase 3 safety trial is on track, with potential NDA submission in 1H calendar 2025. This provides a significant growth opportunity for the company.
News and Updates
Acasti Pharma recently reported earnings per share of -$0.26, beating analyst estimates of -$0.35. The company also announced year-end 2024 financial results, providing a business update and guidance on its cash position.
Upgrades and Downgrades
There have been no recent upgrades or downgrades to Acasti Pharma's stock rating.
Summary
In conclusion, Acasti Pharma presents an attractive opportunity for investors seeking exposure to the growing orphan disease market. While the company's financial performance has been marked by significant losses, its strong cash position and promising product pipeline provide a solid foundation for growth. With a buy rating from one analyst, Acasti Pharma is a stock worth considering for investors with a higher risk tolerance.
Disclosures
The information on this website should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on other content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Under no circumstances should any information provided on this website or social media platforms be construed as an offer soliciting the purchase or sale of any security, nor should it be construed as an offer to provide investment advisory services.